Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Korea; Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Psychiatry Res. 2015 Feb 28;225(3):471-5. doi: 10.1016/j.psychres.2014.11.065. Epub 2014 Dec 9.
Catecholamines such as norepinephrine, epinephrine, and dopamine are closely related to the autonomic nervous system, suggesting that panic disorder may involve elevated catecholamine levels. This study investigated basal and posttreatment catecholamine levels in patients with panic disorder. A total of 29 patients with panic disorder and 23 healthy controls participated in the study. Panic disorder patients received paroxetine treatment for 12 weeks after clinical tests and examination had been conducted. We investigated the difference in basal levels of catecholamine and measured the changes in catecholamine levels before and after drug treatment in panic disorder patients. The basal plasma epinephrine (48.87±6.18 pg/ml) and dopamine (34.87±3.57 pg/ml) levels of panic disorder patients were significantly higher than those (34.79±4.72 pg/ml and 20.40±3.53 pg/ml) of the control group. However, basal plasma norepinephrine levels did not show statistically significant differences between patients and controls. After drug therapy, plasma catecholamine levels were nonsignificantly decreased and norepinephrine levels showed a tendency toward a decrease that did not reach significance. In conclusion, this study suggests the possibility of a baseline increase of plasma catecholamine levels and activation of sympathetic nervous systems in patients with panic disorder which may normalize after treatment with paroxetine.
儿茶酚胺类物质,如去甲肾上腺素、肾上腺素和多巴胺,与自主神经系统密切相关,这表明惊恐障碍可能涉及儿茶酚胺水平升高。本研究调查了惊恐障碍患者的基础和治疗后儿茶酚胺水平。共有 29 名惊恐障碍患者和 23 名健康对照者参与了这项研究。在进行临床测试和检查后,惊恐障碍患者接受了 12 周的帕罗西汀治疗。我们调查了儿茶酚胺基础水平的差异,并测量了惊恐障碍患者药物治疗前后儿茶酚胺水平的变化。惊恐障碍患者的基础血浆肾上腺素(48.87±6.18 pg/ml)和多巴胺(34.87±3.57 pg/ml)水平明显高于对照组(34.79±4.72 pg/ml 和 20.40±3.53 pg/ml)。然而,基础血浆去甲肾上腺素水平在患者和对照组之间没有统计学上的显著差异。药物治疗后,血浆儿茶酚胺水平无显著降低,去甲肾上腺素水平呈下降趋势,但未达到显著水平。总之,这项研究表明惊恐障碍患者的基础血浆儿茶酚胺水平升高和交感神经系统激活的可能性,帕罗西汀治疗后可能会恢复正常。